Assembly Competitors
| ASMB Stock | USD 28.80 0.98 3.52% |
Assembly Biosciences vs Tenaya Therapeutics Correlation
Poor diversification
The correlation between Assembly Biosciences and TNYA is 0.67 (i.e., Poor diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Assembly Biosciences and TNYA in the same portfolio, assuming nothing else is changed.
Moving together with Assembly Stock
Moving against Assembly Stock
| 0.91 | 6C1 | CytomX Therapeutics | PairCorr |
| 0.9 | DRTS | Alpha Tau Medical | PairCorr |
| 0.77 | GXEA | Galapagos NV Earnings Call This Week | PairCorr |
| 0.75 | 8VP1 | AVRICORE HEALTH INC | PairCorr |
| 0.69 | DNTH | Dianthus Therapeutics | PairCorr |
Assembly Biosciences Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Assembly Biosciences and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Assembly and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Assembly Biosciences does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Assembly Stock performing well and Assembly Biosciences Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Assembly Biosciences' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| ZURA | 3.72 | 0.58 | 0.12 | 0.46 | 4.51 | 9.32 | 33.15 | |||
| FHTX | 3.62 | 0.38 | 0.11 | 0.29 | 3.34 | 8.60 | 31.12 | |||
| IMRX | 3.89 | (0.12) | 0.00 | (0.74) | 0.00 | 8.98 | 67.18 | |||
| SGMT | 3.27 | (0.72) | 0.00 | (0.51) | 0.00 | 5.78 | 22.02 | |||
| ENTA | 2.48 | 0.23 | 0.07 | 0.66 | 2.70 | 5.67 | 15.79 | |||
| AARD | 3.82 | 0.20 | 0.06 | 0.11 | 4.42 | 9.35 | 38.95 | |||
| NAUT | 4.56 | 0.93 | 0.17 | (2.57) | 4.34 | 9.85 | 28.35 | |||
| ARCT | 2.91 | (0.28) | 0.00 | (0.07) | 0.00 | 6.53 | 15.98 | |||
| PYXS | 5.90 | (1.39) | 0.00 | (0.94) | 0.00 | 9.23 | 66.31 | |||
| TNYA | 5.09 | (1.07) | 0.00 | (0.25) | 0.00 | 9.02 | 48.07 |
Cross Equities Net Income Analysis
Compare Assembly Biosciences and related stocks such as Zura Bio Limited, Foghorn Therapeutics, and Immuneering Corp Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ZURA | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | (25.7 M) | (60.4 M) | (52.4 M) | (47.2 M) | (49.5 M) |
| FHTX | (26.3 M) | (26.3 M) | (26.3 M) | (26.3 M) | (26.3 M) | (26.3 M) | (26.3 M) | (26.3 M) | (26.3 M) | (51.1 M) | (68.8 M) | (101.3 M) | (108.9 M) | (98.4 M) | (86.6 M) | (78 M) | (81.9 M) |
| IMRX | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (17 M) | (33.5 M) | (50.5 M) | (53.5 M) | (61 M) | (54.9 M) | (57.7 M) |
| SGMT | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (11.4 M) | (24.4 M) | (30.5 M) | (27.9 M) | (45.6 M) | (41 M) | (43.1 M) |
| ENTA | 7.9 M | 21.4 M | 9.6 M | 34.4 M | 79 M | 21.7 M | 17.7 M | 72 M | 46.4 M | (36.2 M) | (79 M) | (121.8 M) | (133.8 M) | (116 M) | (81.9 M) | (73.7 M) | (70 M) |
| AARD | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (7.2 M) | (20.6 M) | (18.5 M) | (19.5 M) |
| NAUT | 626.6 M | 626.6 M | 626.6 M | 626.6 M | 626.6 M | 626.6 M | 626.6 M | 626.6 M | 626.6 M | (9.6 M) | (15.6 M) | (50.3 M) | (57.9 M) | (63.7 M) | (70.8 M) | (63.7 M) | (60.5 M) |
| ARCT | (3.9 M) | (3.9 M) | (1.6 M) | (10.5 M) | (32.8 M) | (19.4 M) | (24.6 M) | (10.9 M) | (21.8 M) | (26 M) | (72.1 M) | (203.7 M) | 9.3 M | (29.7 M) | (80.9 M) | (72.8 M) | (69.2 M) |
| PYXS | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (12.8 M) | (76 M) | (118 M) | (73.8 M) | (77.3 M) | (69.6 M) | (73.1 M) |
| TNYA | (25.8 M) | (25.8 M) | (25.8 M) | (25.8 M) | (25.8 M) | (25.8 M) | (25.8 M) | (25.8 M) | (25.8 M) | (25.8 M) | (38.4 M) | (69.7 M) | (123.7 M) | (124.1 M) | (111.1 M) | (100 M) | (105 M) |
Assembly Biosciences and related stocks such as Zura Bio Limited, Foghorn Therapeutics, and Immuneering Corp Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Assembly Biosciences financial statement analysis. It represents the amount of money remaining after all of Assembly Biosciences operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Assembly Biosciences Competitive Analysis
The better you understand Assembly Biosciences competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Assembly Biosciences' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Assembly Biosciences' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Assembly Biosciences Competition Performance Charts
Five steps to successful analysis of Assembly Biosciences Competition
Assembly Biosciences' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Assembly Biosciences in relation to its competition. Assembly Biosciences' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Assembly Biosciences in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Assembly Biosciences' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Assembly Biosciences, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Assembly Biosciences position
In addition to having Assembly Biosciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Aggressive Defence Thematic Idea Now
Aggressive Defence
Macroaxis small cap, aggressive-outlook picks designed for investors that are willing to accept higher levels of risk to hedge exposure to above-average market volatility. The Aggressive Defence theme has 50 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Aggressive Defence Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Assembly Biosciences Correlation with its peers. For information on how to trade Assembly Stock refer to our How to Trade Assembly Stock guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Assembly Biosciences. If investors know Assembly will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Assembly Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (4.60) | Revenue Per Share | Quarterly Revenue Growth 0.576 | Return On Assets | Return On Equity |
Assembly Biosciences's market price often diverges from its book value, the accounting figure shown on Assembly's balance sheet. Smart investors calculate Assembly Biosciences' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Assembly Biosciences' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that Assembly Biosciences' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Assembly Biosciences represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, Assembly Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.